The amount of cDCs in the blood at 3 months posttransplant predicts survival after allogeneic HSCT from unrelated donors. (A) Multivariate analysis showing the hazard ratios (HRs) for the numbers of viable T cells, T-cell subsets, B cells, NK cells, DC subsets (cDCs/myeloid DCs and pDCs), CD4⁺ and CD8⁺ TREC, and plasma IL-2 and IL-7 levels with OS for recipients of G-PB grafts. (B) Multivariate analysis showing HRs for the numbers of immune cells and plasma cytokine levels with OS for recipients of BM grafts. (C) Estimated probability of 3-year OS, stratifying 291 evaluable recipients of BM and G-PB grafts by the median number of cDCs in blood samples at 3 months posttransplant. (D) Estimated probability of 3-year OS by the median number of pDCs in blood samples at 3 months posttransplant.